缬沙坦联合氟伐他汀治疗肾性高血压的临床观察

Clinical evaluation of valsartan combined fluvastatin for the patients with renal hypertension

目的:观察缬沙坦与氟伐他汀联合应用对慢性肾病继发性高血压的治疗作用。方法:58例肾性高血压患者被随机分成两组,每组29例:在慢性肾病常规治疗基础上,缬沙坦对照组给予缬沙坦80mg1次/d口服,联合用药组在缬沙坦对照组的基础上加用氟伐他汀40mg1次/d口服,疗程8周。观察治疗前后血压、血肌酐(Scr)、尿素氮(BUN)、24h尿蛋白定量以及血脂的变化。结果:治疗后两组血压、Scr、BUN、24h尿蛋白均显著下降(P<0.01),肾功能明显改善,联合用药组Scr[(286.37±84.72):(327.52±92.63)μmol/L]、BUN[(8.35±5.24):(9.46±6.14)mmol/L]、24h尿蛋白[(0.89±0.71):(1.52±0.84)g/L]、血脂均较缬沙坦对照组显著下降(P均<0.05)结论:缬沙坦与氟伐他汀联合应用能有效减轻肾病高血压患者的肾脏损害,其疗效优于单用缬沙坦治疗。

Objective： To investigate the therapeutic effects of valsartan combined fluvastatin for secondary hypertension following chronic renal disease. Methods： The 58 patients with secondary hypertension following chronic renal disease were randomly divided into two groups which were 29 patients for each group： The patients of valsartan control group took valsartan 80 rag/d, combined therapeutic group took valsartan 75 mg/d and fluvastatin 40 mg/d within 8 weeks. Blood pressure, serum creatinine （Scr）, blood urea nitrogen （BUN）, 24h urine protein, and blood lipid were observed before and after treatment. Results： The Blood pressure, Scr, BUN, 24h urine protein and blood lipid levels significantly decreased （P〈0.01） after treatment in both groups. Furthermore, the levels of Scr [ （286.37±84.72） /1tool/ L vs. （327.52±92.63） μmol/L], BUN [ （8.35±5.24） mmol/L vs. （9.46±6. 14） mmol/L], and 24h urine protein E （0.89±0. 71） g/L vs. （1.52 0.84） g/L] and blood lipid in combined therapeutic group significantly decreased compared with those of valsartan control group （P〈0.05 all）. Conclusion： It would effectively reduce the renal lesion that valsartan combined fluvastatin to treat patients with secondary hypertension following chronic renal disease, which would be better than taking valsartan only.